SELLAS Life Sciences Group, Inc. $SLS Stock: Vision Financial Markets LLC Raises Holdings

Vision Financial Markets LLC lifted its position in SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) by 481.6% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 57,000 shares of the company’s stock after purchasing an additional 47,200 shares during the quarter. SELLAS Life Sciences Group accounts for approximately 0.5% of Vision Financial Markets LLC’s holdings, making the stock its 29th biggest holding. Vision Financial Markets LLC’s holdings in SELLAS Life Sciences Group were worth $702,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in SLS. Dagco Inc. raised its stake in shares of SELLAS Life Sciences Group by 19.8% in the second quarter. Dagco Inc. now owns 1,232,433 shares of the company’s stock valued at $18,191,000 after acquiring an additional 203,653 shares during the last quarter. Wellington Management Group LLP increased its holdings in SELLAS Life Sciences Group by 73.2% during the 2nd quarter. Wellington Management Group LLP now owns 597,309 shares of the company’s stock valued at $8,816,000 after purchasing an additional 252,531 shares in the last quarter. Bank of New York Mellon Corp acquired a new stake in SELLAS Life Sciences Group during the 2nd quarter valued at $7,823,000. Bank of America Corp DE raised its position in SELLAS Life Sciences Group by 535.7% in the 1st quarter. Bank of America Corp DE now owns 641,683 shares of the company’s stock valued at $2,714,000 after purchasing an additional 540,748 shares during the last quarter. Finally, Tidal Investments LLC raised its position in SELLAS Life Sciences Group by 43.1% in the 2nd quarter. Tidal Investments LLC now owns 128,761 shares of the company’s stock valued at $1,901,000 after purchasing an additional 38,754 shares during the last quarter. Institutional investors and hedge funds own 17.38% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on SLS shares. Alliance Global Partners restated a “buy” rating on shares of SELLAS Life Sciences Group in a report on Wednesday, August 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a report on Thursday, October 15th. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $10.00.

SELLAS Life Sciences Group Stock Performance

Shares of NASDAQ SLS traded up $0.19 during trading on Friday, reaching $11.54. The company had a trading volume of 3,264,461 shares, compared to its average volume of 5,695,020. SELLAS Life Sciences Group, Inc. has a 52 week low of $1.39 and a 52 week high of $15.88. The business’s 50 day moving average price is $12.43 and its 200-day moving average price is $10.15. The stock has a market cap of $2.33 billion, a PE ratio of -54.95 and a beta of 2.56.

SELLAS Life Sciences Group (NASDAQ:SLS) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.05) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.01).

SELLAS Life Sciences Group Company Profile

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on developing novel cancer therapies. The company’s research and development programs are centered on treatments designed to stimulate or restore the immune system’s ability to recognize and attack cancer cells, as well as targeted therapies for hematologic malignancies.

SELLAS’ lead product candidate is galinpepimut-S (GPS), a multi-peptide immunotherapeutic targeting Wilms’ tumor 1 (WT1), a protein expressed in multiple types of cancer.